New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
May 14, 2014
05:38 EDTAZN, INCYIncyte, MedImmune collaborate on immuno-oncology combination clinical trial
Incyte (INCY) and MedImmune, the global biologics research and development arm of AstraZeneca (AZN), announced that they have entered into a clinical study collaboration. The Phase I/II oncology study will evaluate the efficacy and safety of MedImmune’s investigational anti-PD-L1 immune checkpoint inhibitor, MEDI4736, in combination with Incyte’s oral indoleamine dioxygenase-1 inhibitor, INCB24360. Under the terms of the agreement, MedImmune and Incyte will collaborate on a non-exclusive basis on the study, to evaluate the combination in multiple solid tumors including metastatic melanoma, non-small cell lung cancer, squamous cell carcinoma of the head and neck and pancreatic cancer. The Phase I part of the trial is expected to establish a recommended dose regimen of both MEDI4736 and INCB24360 and the Phase II part of the study will assess the safety and efficacy of the combination. Results from the study will be used to determine whether further clinical development of this combination is warranted. The study will be co-funded equally by Incyte and MedImmune and conducted by Incyte.
News For INCY;AZN From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
April 17, 2015
07:33 EDTINCYIncyte no longer expects to initiate INCB39110 trial in pancreatic cancer in '15
Incyte Corporation announced that eleven abstracts detailing its emerging development pipeline will be presented at the 2015 American Association for Cancer Research Annual Meeting in Philadelphia, PA. These abstracts include characterizations of Incyte’s FGFR, BRD and PIM inhibitors as potential targeted therapies for cancer, as well as data supporting the potential immuno-therapeutic activity of the company’s portfolio of JAK and PI3Kδ inhibitors alone and in combination, including with epacadostat, Incyte’s leading IDO1 inhibitor. The company also provided an updated presentation of its clinical portfolio, which now includes INCB54828, a potent and selective FGFR inhibitor and INCB50465, a PI3Kδ inhibitor, which entered clinical trials in Q1 2015 for solid tumors and B-lymphoid malignancies. INCB54329, a bromodomain inhibitor, is expected to enter clinical trials in Q2 2015 in hematology oncology. Additional first-line pancreatic cancer patients are being recruited into the expansion cohort of JAK1-selective inhibitor INCB39110 in combination with gemcitabine and nab-paclitaxel to continue the dose optimization phase of this proof-of-concept trial. Incyte therefore no longer expects to initiate a pivotal trial of INCB39110 in first-line pancreatic cancer during 2015.
06:52 EDTAZNAstraZeneca granted FDA orphan drug designation for selumetinib
AstraZeneca announced that the FDA has granted orphan drug designation for the MEK inhibitor selumetinib, for the treatment of uveal melanoma, a rare disease in which cancer cells form in the tissues of the eye.
06:50 EDTAZNAstra reports median progression free survival of 13.5 months in AURA study
Subscribe for More Information
April 16, 2015
09:12 EDTAZNAstraZeneca granted orphan status for melanoma treatment
Subscribe for More Information
07:58 EDTAZNAstraZeneca's MedImmune, Immunocore announce new collaboration agreement
Subscribe for More Information
April 15, 2015
11:50 EDTAZNAstraZeneca initiated with a Buy at Societe Generale
07:41 EDTAZNEBD Group to hold a forum
ChinaBio Partnering Forum 2015 is being held in Shanghai, China on April 15-16.
April 14, 2015
12:06 EDTAZNFDA panel accepts Onglyza's safety profile in 13-1 vote
Subscribe for More Information
07:31 EDTINCYIncyte to establish European headquarters in Geneva, Switzerland
Subscribe for More Information
07:15 EDTAZNFDA Endocrinologic & Metabolic Drugs Advisory Committee holds a meeting
Subscribe for More Information
April 13, 2015
08:58 EDTAZNMerck may have positive read through from briefing docs, says SunTrust
Subscribe for More Information
08:54 EDTAZNAstraZeneca has negative read through from briefing docs, says SunTrust
Subscribe for More Information
April 10, 2015
10:36 EDTAZNAstraZeneca trades lower, levels to watch
Shares are down less than 1% to $69.54 at time of writing. At that price the stock is just above the 50-day moving average at $69.12. Since May of last year, price has oscillated around the 50-day, with the average acting as the approximate center line. Support below the 50-day is at $68.24.
09:25 EDTAZNFDA staff say analysis suggests Onglyza may increase risk of death
Subscribe for More Information
April 9, 2015
09:25 EDTAZNPiper Jaffray pharmaceuticals analysts hold an analyst/industry conference call
Subscribe for More Information
April 8, 2015
06:06 EDTAZNInovio selected by DARPA to lead $45M Ebola prevention program
Subscribe for More Information
April 7, 2015
16:12 EDTAZNRegulus up 5% after RG-125 selected as clinical candidate by AstraZeneca
Subscribe for More Information
16:12 EDTAZNRegulus RG-125 selected as clinical candidate by AstraZeneca
Regulus Therapeutics (RGLS) announced the selection of RG-12, a GalNAc-conjugated anti-miR targeting microRNA-103/107, or miR-103/107, for the treatment of Non Alcoholic Steatohepatitis, or NASH, in patients with type 2 diabetes/pre-diabetes, as a clinical candidate by AstraZeneca (AZN) under the companies' strategic alliance to discover, develop and commercialize microRNA therapeutics. RG-125 is the first compound from the alliance to be selected for clinical development by AstraZeneca. In connection with the candidate selection, AstraZeneca will pay Regulus $2.5M and will assume development of the program following acceptance of an Investigational New Drug application. In the near term, Regulus and AstraZeneca plan to submit key preclinical data on the RG-125 program to be presented at a scientific meeting later this year and expect to initiate a Phase I study of RG-125 in humans by the end of 2015.
07:14 EDTAZNEyeforpharma to hold a summit
Philadelphia 2015 Commercial Pharma Summit is being held in Philadelphia on April 7-8.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use